The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.
Intra-Cellular Therapies’ pipeline is focused on the following platforms: lumateperone and follow-on compounds, ITI-1284-ODT-SL, phosphodiesterase 1 (PDE1) inhibitors and ITI-333, a novel compound that acts as a partial agonist at mu-opioid (MOP) receptors and as an antagonist at the serotonin 5-HT2A receptors.